143 related articles for article (PubMed ID: 31261533)
41. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
42. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
43. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
[TBL] [Abstract][Full Text] [Related]
44. Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Hunter NB; Vogt S; Ambinder RF
Oncology (Williston Park); 2017 Dec; 31(12):872-7, 884. PubMed ID: 29297171
[TBL] [Abstract][Full Text] [Related]
45. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
46. False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Ford CD; Gabor F; Morgan R; Dabbas B
Clin Nucl Med; 2006 Jul; 31(7):391-3. PubMed ID: 16785805
[TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
Rödel S; Engert A; Diehl V; Reiser M
Leuk Lymphoma; 2005 Dec; 46(12):1729-34. PubMed ID: 16353313
[TBL] [Abstract][Full Text] [Related]
48. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.
Bayraktar UD; Ramos JC; Petrich A; Gupta N; Lensing S; Moore PC; Reid EG; Aboulafia DM; Ratner L; Mitsuyasu R; Cooley T; Henry DH; Barr P; Noy A
Leuk Lymphoma; 2012 Dec; 53(12):2383-9. PubMed ID: 22642936
[TBL] [Abstract][Full Text] [Related]
49. Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
Mak YK; Chan CH; Li CK; Lee MP; Tsang YW
Hong Kong Med J; 2003 Apr; 9(2):91-7. PubMed ID: 12668818
[TBL] [Abstract][Full Text] [Related]
50. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
[TBL] [Abstract][Full Text] [Related]
51. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
52. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
[TBL] [Abstract][Full Text] [Related]
53. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
54. A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.
Kassam S; Bower M; Lee SM; de Vos J; Fields P; Gandhi S; Nelson M; Montoto S; Tenant-Flowers M; Burns F; Marcus R; Edwards SG; Cwynarski K
Leuk Lymphoma; 2013 Sep; 54(9):1921-7. PubMed ID: 23206228
[TBL] [Abstract][Full Text] [Related]
55. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
56. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
57. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
58. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
Hentrich M; Hoffmann C; Mosthaf F; Müller M; Siehl J; Wyen C; Hensel M; ;
Ann Hematol; 2014 Jun; 93(6):913-21. PubMed ID: 24807241
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
Straus DJ
Recent Results Cancer Res; 2002; 159():143-8. PubMed ID: 11785838
[TBL] [Abstract][Full Text] [Related]
60. [Lymphomas associated with HIV infection in patients at the Hospital San Borja Arriarán /Fundación Arriarán 2001-2008, Santiago, Chile].
Pizarro A; García H; Riquelme A; Carmona J; Cortés C
Rev Chilena Infectol; 2013 Feb; 30(1):23-30. PubMed ID: 23450406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
